New York, NY (PRWEB) August 01, 2012
Ceres Ventures, Inc. (OTCQB: CEVE) (the “Company”) a development stage company currently engaged in identifying, acquiring and developing a comprehensive portfolio of technologies relating to clean resources technologies, announced today that the Company, through its subsidiary, BluFlow™ Technologies, Inc. has developed a proprietary process to produce commercial scale volumes of the Company’s specialized BluFlow™ nanoparticles and has filed a new patent to strengthen the intellectual property protection around its BluFlow™ water treatment technology, which is now the subject of four (4) patent filings.
The Company also announced that, in conjunction with a major United States Professional Engineering & Consulting Firm serving numerous clients, including Fortune 50 & 100 clients, it is conducting a treatability study of its BluFlow™ Treatment System for the treatment of contaminated groundwater as a necessary step in anticipation of upcoming field tests at sites to be designated by the Engineering Firm.
The Company’s treatability study is focused on removing two (2) organic compounds currently identified in ground water at the facilities of one of the Engineering Firm’s clients. The first compound is listed on the United States Environmental Protection Agency, Safe Drinking Water Act as a regulated contaminated. The second compound is listed in the U.S. Department of Health and Human Services 12th Report on Carcinogens (June 10, 2011) “as reasonably anticipated to be a human carcinogen” and identified as a contaminant in water at sites throughout the United States. Moreover, this compound has been considered a chemical “known to the State of California to cause cancer” under Proposition 65, and is suspected as a kidney toxicant, neurotoxicant and respiratory toxicant, according to the California Environmental Protection Agency.
“Today, with the introduction of the new patent pending process and equipment developed by our engineers for producing customized absorbent nanoparticles at commercial scale quantities while maintaining the quality control necessary to produce BluFlow™ nanoparticles that are consistent and uniform in shape and size, we have achieved a significant milestone in moving one step closer to our goal of advancing our proprietary BluFlow™ Water Treatment System towards commercialization,” stated Meetesh Patel, the Company’s Chief Executive Officer.
“We are excited to be working in conjunction with a major national independent engineering firm for the anticipated feasibility treatment studies to address an existing remedial investigation for the site to consider the use of the BluFlow™ Treatment System for contaminated groundwater cleanup. The Company is now poised to shift its focus on achieving another milestone by advancing our technology further down the commercialization pipeline by moving forward with our plans to scale up and field test our BluFlow™ Water Treatment System” concluded Mr. Patel.
The Company’s patent-pending BluFlow™ Treatment System is a first-of-its-kind single integrated treatment solution that simultaneously removes specific target chemicals/pollutants or valuable elements and compounds at very high efficiencies while purifying up to 95% of the remaining water for reuse based on a novel recirculation system that has minimal reject wastewater.
About Ceres Ventures, Inc.
Ceres Ventures, Inc., together with its wholly owned subsidiaries is a developer of next generation clean technologies for the remediation and purification of water, air, and soil.
Over time, the Company seeks to actively deliver environmental remediation systems and services to address the water, air and soil markets. Based on the essential nature of water, the Company’s initial focus is on the water market.
For additional information, please visit: http://www.ceresventures.com
To view the full HTML text of this release, please visit: http://www.ceresventures.com/ceres-ventures-achieves-important-milestone/
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Ceres Ventures, Inc. (the “Company” or Ceres Ventures”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Ceres Ventures will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.